Apolipoprotein A I/APOA1 Antibody (A5.4): sc-13549

apoA-I Antibody (A5.4) is a mouse monoclonal IgG1 antibody that detects apolipoprotein A-I in human samples through various applications including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and immunohistochemistry. ApoA-I is a crucial component of high-density lipoprotein (HDL) in plasma, consisting of a single chain of 243 amino acids that plays a vital role in cholesterol metabolism by promoting the efflux of cholesterol from peripheral tissues to the liver for excretion. This process is essential for maintaining lipid homeostasis and preventing atherosclerosis, a condition characterized by the buildup of fats, cholesterol, and other substances in and on the artery walls. Additionally, apoA-I serves as a cofactor for lecithin cholesterol acyltransferase (LCAT), an enzyme that catalyzes the formation of cholesteryl esters, further facilitating the transport and metabolism of lipids. The importance of apoA-I extends beyond its structural role; apoA-I is also involved in the regulation of plasma triglyceride levels and influences the activity of other apolipoproteins, making apoA-I a key player in cardiovascular health. With apoA-I′s ability to interact with various lipid molecules and enzymes, apoA-I is not only a marker for HDL but also a significant factor in understanding lipid-related diseases.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Apolipoprotein A I/APOA1 Antibody (A5.4) References:

1. The apoA-I mimetic peptide 4F protects apolipoprotein A-I from oxidative damage.  |  White, CR., et al. 2019. Chem Phys Lipids. 219: 28-35. PMID: 30707910
2. Apolipoprotein A-I (ApoA-I), Immunity, Inflammation and Cancer.  |  Georgila, K., et al. 2019. Cancers (Basel). 11: PMID: 31374929
3. Endogenous ApoA-I expression in macrophages: A potential target for protection against atherosclerosis.  |  Chen, W., et al. 2020. Clin Chim Acta. 505: 55-59. PMID: 32092318
4. Autophagy Alteration in ApoA-I Related Systemic Amyloidosis.  |  Del Giudice, R., et al. 2022. Int J Mol Sci. 23: PMID: 35408859
5. Human apoA-I[Lys107del] mutation affects lipid surface behavior of apoA-I and its ability to form large nascent HDL.  |  Gorshkova, IN., et al. 2023. J Lipid Res. 64: 100319. PMID: 36525992
6. ApoA-I and Diabetes.  |  King, TW., et al. 2023. Arterioscler Thromb Vasc Biol. 43: 1362-1368. PMID: 37381981
7. Association of oxidized ApoB and oxidized ApoA-I with high-risk coronary plaque features in cardiovascular disease.  |  Sorokin, AV., et al. 2023. JCI Insight. 8: PMID: 37698922
8. ApoA-I Protects Pancreatic β-Cells From Cholesterol-Induced Mitochondrial Damage and Restores Their Ability to Secrete Insulin.  |  Manandhar, B., et al. 2024. Arterioscler Thromb Vasc Biol. 44: e20-e38. PMID: 38095105
9. ApoA-I and ApoB levels, and ApoB-to-ApoA-I ratio as candidate pre-treatment biomarkers of pathomorphological response to neoadjuvant therapy in gastric and esophago-gastric junction adenocarcinoma.  |  Nurczyk, K., et al. 2023. Pol Przegl Chir. 96: 44-49. PMID: 38629280
10. ApoA-I Infusions and Burden of Ischemic Events After Acute Myocardial Infarction: Insights From the AEGIS-II Trial.  |  Gibson, CM., et al. 2024. J Am Coll Cardiol. 84: 2185-2192. PMID: 39230545

The preferred Apolipoprotein A I/APOA1 antibody is Apolipoprotein A I/APOA1 Antibody (B-10): sc-376818.